What happened to ocgn stock?
Apr 24, 2022 · OpGen's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPGN stock has decreased by 78.5% and is now trading at $0.4447. View which stocks have been most impacted by …
What happened to Opgen stock after the January split?
Apr 27, 2022 · americanbankingnews.com - April 17 at 1:20 AM. OpGen, Inc. (NASDAQ:OPGN) Short Interest Up 211.3% in March. americanbankingnews.com - April 13 at 3:08 AM. OpGen Announces Interim Analysis Results From Clinical Trial For Unyvero Urinary Tract Infection Panel - …
What is Opgen's (opgn) stock price?
Mar 08, 2021 · OPGN stock was up 74.5% as of Monday morning. On the date of publication, William White did not have (either directly or indirectly) any …
How much of Opgen's stock is owned by insiders?
Dec 28, 2021 · OPGN is lower by -$0.06 from the previous closing price of $1.11 on volume of 187,614 shares. Over the past year the S&P 500 has gained 28.32% while OPGN is lower by -38.24%. OPGN lost -$1.18 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for OpGen Inc click here.
Is OPGN a good investment?
The 1 analysts offering 12-month price forecasts for OpGen Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +681.25% increase from the last price of 0.51.
Will OPGN go up?
Based on 1 Wall Street analysts offering 12 month price targets for OpGen in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 513.97% change from the last price of $0.65.
When did OPGN go public?
Did OpGen get FDA approval?
OpGen Media Sentiment
Media Coverage
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
OpGen (NASDAQ OPGN) News Headlines Today
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
What happened
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
So what
Shares of biopharmaceutical company Ocugen ( NASDAQ:OCGN) dropped by 31.1% in May, according to S&P Global Market Intelligence data. Investors were concerned because the downward trend in COVID-19 cases in the United States could hurt the chances for the company's vaccine, which it is developing with India's Bharat Bioscience.
Now what
Ocugen's stock is up by more than 3,389% over the past 12 months and more than 376% this year. Those massive gains were predicated on the possibility that its candidate coronavirus vaccine COVAXIN, which the company says is effective against the new COVID-19 variants of concern, would be approved -- and be profitable.
How much is Opgen revenue in 2021?
There's a lot of risk involved with this biotech stock. There's a good possibility that COVAXIN may not be granted an EUA, based on the FDA's recent statement. Even if it does get that EUA, Ocugen's vaccine is coming late to the party, putting it at a significant disadvantage to the entrenched COVID-19 vaccines, at least in the U.S. market.
What is Opgen 2021?
Total OpGen revenue for the first quarter of 2021 was approximately $830,000, up 34.5% from $617,000 in the first quarter of 2020. Cash as of March 31, 2021 was approximately $39.4 million, up significantly from the $13.4 million at year-end 2020.
Ocugen Merger Has Failed to Turn Stock Around
(Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that it has submitted an updated 510 (k) summary document to the U.S. FDA for its Acuitas AMR Gene Panel for Isolates. This document incorporates all of the FDA’s requested updates to various key documents such as the Package Insert, Electronic User Guide, and Operator Ma
OCGN Is an Overpriced Cheap Stock
For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. The equity has experienced a continual decline for years. It peaked at a split-adjusted level of around $778 per share soon after its initial public offering in 2014.
Bottom Line: Avoid Ocugen Stock
Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open.
